Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients.

Next Previous
Search
Trial Profile

Acute Effects of SCH 420814 on Dyskinesia and Parkinsonism in Levodopa Treated Patients.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Preladenant (Primary) ; Carbidopa; Levodopa
  • Indications Drug-induced dyskinesia; Parkinson's disease
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 15 Jul 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 25 Dec 2009 Planned end date changed from 1 Dec 2009 to 1 May 2010 as reported by ClinicalTrials.gov.
  • 21 Aug 2009 Additional locations identified as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top